Verinomics
New Haven, US · Founded 2016 · Delaware corporation · 16 employees on LinkedIn · 2 known investors
Verinomics develops crop improvement technology by combining genomics, computational biology, and a transgene-free gene editing platform, with an AI-driven population genomics tool to identify high-value trait genes. It serves breeding programs, agricultural businesses, and research institutions focused on specialty and vegetatively propagated crops such as leafy greens.
Also known as Verinomics, Inc.
Founders & leadership
Verinomics was founded in 2016 by Stephen Dellaporta.
Investors · 2
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 round · 2018
▶$2MraisedJan 2019 · 2 investors · OtherRule 506(b)
- Stephen DellaportaExecutive Officer, Director
- Christopher HeffelfingerExecutive Officer
- Mat MullerDirector
- James ZhuDirector
- Offering amount
- $3M
- Amount sold
- $2M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Verinomics is an agricultural genomics and gene editing company based at 5 Science Park in New Haven, Connecticut. It works on crop improvement by combining chromosome-level genome assemblies, population genomics, AI-based trait identification, computational biology and precision transgene-free gene editing to develop enhanced varieties of fruits, vegetables and tree nuts. The company markets two platforms launched in March 2025: Genesis™, a transgene-free gene editing platform aimed primarily at vegetatively propagated crops, and Genova™, a genomic-driven breeding acceleration platform that uses genomic selection and predictive modeling for both seed and vegetatively propagated crops. A separate AI-driven population genomics capability is used for trait discovery, identifying the genetic architecture of high-value traits to inform breeding decisions.
The company positions its editing approach as non-GMO trait development that avoids introducing foreign DNA and is intended to align with global regulatory frameworks. Stated target outcomes include disease resistance, resource efficiency and sustainability, and improved nutritional profiles. Verinomics is classified in biotechnology research (SIC 8731; NAICS 541714).
Founding story
Verinomics was founded by Dr. Stephen Dellaporta, its President and Founder and a professor at Yale University, who described the founding vision as harnessing genomic technologies to address urgent agricultural challenges. Co-founders listed by the company include Chris Heffelfinger (Director of Computational Biology), Brian Staskawicz (gene editing advisor) and Maria Moreno (genomics advisor).
Business model
Verinomics describes a partner-first, co-development model: it works with nurseries, seed companies, growers and producers to identify high-value traits with clear market benefits and to co-develop products, with shared intellectual property arrangements. Announced work includes multi-year collaborations and strategic partnerships with germplasm providers.
Traction
As of the March 2025 platform launch announcement, the company reported $13 million raised, a genomics-driven breeding and transgene-free editing pipeline, several key partnerships and proprietary product development tools. Its almond self-compatibility work with Burchell Nursery was described as producing the Nonpareil+ almond variety, for which Burchell Nursery was taking first-come, first-served orders for 2027. A board member characterized the company as having commercial traction as it prepared to raise growth capital.
Latest developments
In March 2025 Verinomics unveiled its Genesis™ and Genova™ platforms and stated it was preparing growth financing to scale them, expand into new high-value crop sectors and broaden adoption of non-GMO breeding solutions. In May 2025 it announced a strategic partnership with Pinnacle Seed to advance leafy green innovation using elite genetics and transgene-free gene editing.
▸Full profile — market position, technology, go-to-market, geography
Market position
Verinomics focuses on specialty crops, including vegetatively propagated crops and tree nuts, segments it describes as historically underserved by conventional breeding and transgenic approaches. Third-party profiling places it in biotechnology research with roughly 11-50 employees.
The company emphasizes transgene-free editing that avoids foreign DNA and is presented as non-GMO and compatible with global regulatory frameworks, applicability to vegetatively propagated crops, and a needs-first approach that begins with producer and consumer requirements before developing tailored solutions, with shared IP in co-development deals.
Technology
The technology stack combines chromosome-level genome assemblies, population genomics, AI-based trait identification and transgene-free gene editing. Genesis™ provides precise gene editing across multiple crops, including vegetatively propagated crops that are constrained by conventional breeding. Genova™ applies AI and computational biology to genomic selection and trait identification in order to shorten breeding cycles for seed and vegetatively propagated crops. The company states its editing produces varieties without introducing foreign DNA.
Go-to-market
Verinomics reaches the market through direct partnerships and co-development agreements with supply-chain participants such as nurseries, seed companies and growers, rather than through standalone product sales. Examples include a multi-year collaboration with Burchell Nursery, an almond nursery in the United States, and a May 2025 strategic partnership with Pinnacle Seed in leafy greens.
Breeders and germplasm providers, nurseries, seed companies, agricultural innovators, growers and producers, consumer packaged goods and food brands, and research institutions and investors in the specialty crop value chain.
Geography
Headquartered in New Haven, Connecticut, United States, with partnerships in United States agriculture, including an almond nursery collaboration; third-party data places its workforce in North America.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Verinomics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsVerinomics and Pinnacle Seed announced a strategic partnership to accelerate leafy green innovation using elite genetics and transgene-free gene editing.
In its platform launch announcement, Verinomics stated it had raised $13 million and was preparing for growth financing.
$13M source ↗
Verinomics disclosed a multi-year collaboration with Burchell Nursery, an almond nursery in the United States, applying gene editing to almond self-compatibility; Burchell Nursery was taking orders for the Nonpareil+ almond variety for 2027.
Verinomics unveiled Genesis™, a transgene-free gene editing platform primarily for vegetatively propagated crops, and Genova™, a genomic-driven breeding acceleration platform for seed and vegetatively propagated crops.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 6
primary sources listed
- Verinomicsverinomics.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Verinomics do?
- Verinomics applies genomics, computational biology and transgene-free gene editing to develop improved specialty crop varieties.
- Who founded Verinomics?
- Verinomics was founded by Stephen Dellaporta in 2016.
- Who are Verinomics's investors?
- Verinomics's investors include Cleveland Avenue, Fulcrum Global Capital.
- How much funding has Verinomics raised?
- Verinomics has disclosed $2M raised across 1 round.
- Where is Verinomics headquartered?
- Verinomics is headquartered in New Haven, US.